PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35388835-3	2022	DMPA specifically entered tumor cells through AA-mediated receptor endocytosis; PEI dissociated from the surface of the MSN in the acidic environment of cellular lysosomes/endosomes due to protonation of PEI, resulting in steady release of the encapsulated DOX from the pores of MSN in the cytoplasm of the target cells.	Doxorubicin	257-260	moesin	Homo sapiens	120-123	
35151045-2	2022	The MNBA grafted nanoparticle MSN-SS-MNBA shows excellent blocking performance with negligible leakage when loaded with doxorubicin (DOX), and the release profiles illustrate stimuli-responsive property when triggered by GSH.	Doxorubicin	120-131	moesin	Homo sapiens	30-33	
35388835-2	2022	Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA).	Doxorubicin	61-72	moesin	Homo sapiens	33-36	
35388835-2	2022	Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA).	Doxorubicin	61-72	moesin	Homo sapiens	108-111	
35388835-2	2022	Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA).	Doxorubicin	61-72	moesin	Homo sapiens	231-234	
35388835-2	2022	Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA).	Doxorubicin	74-77	moesin	Homo sapiens	108-111	
35388835-2	2022	Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA).	Doxorubicin	74-77	moesin	Homo sapiens	231-234	
35151045-2	2022	The MNBA grafted nanoparticle MSN-SS-MNBA shows excellent blocking performance with negligible leakage when loaded with doxorubicin (DOX), and the release profiles illustrate stimuli-responsive property when triggered by GSH.	Doxorubicin	133-136	moesin	Homo sapiens	30-33	
32553643-7	2020	DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment.	Doxorubicin	0-3	moesin	Homo sapiens	4-7	
32553643-7	2020	DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment.	Doxorubicin	75-78	moesin	Homo sapiens	4-7	
32553643-7	2020	DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment.	Doxorubicin	75-78	moesin	Homo sapiens	4-7	
32553643-7	2020	DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment.	Doxorubicin	75-78	moesin	Homo sapiens	4-7	
32290047-12	2020	The results suggest that GQDs nanoparticles would be suitable for the delivery of other multidrug resistance protein 1 (MRP1) substrate drugs that bind to the transporter at the same binding pocket, while MSN can strongly inhibit doxorubicin efflux by MRP1.	Doxorubicin	230-241	moesin	Homo sapiens	205-208	
32223128-3	2020	Briefly, mesoporous silica materials (MSN) loaded with doxorubicin (DOX) and phorbol 12-myristate 13-acetate (PMA) was used as drug carrier and could be specifically opened by nucleolin in HeLa cell.	Doxorubicin	55-66	moesin	Homo sapiens	38-41	
32223128-3	2020	Briefly, mesoporous silica materials (MSN) loaded with doxorubicin (DOX) and phorbol 12-myristate 13-acetate (PMA) was used as drug carrier and could be specifically opened by nucleolin in HeLa cell.	Doxorubicin	68-71	moesin	Homo sapiens	38-41	
32329202-8	2020	In vitro cytotoxicity assay indicates that DOX loaded mixture nanoparticles (ratio of PLL-MSN to PLG-MSN is 1:1) can be triggered for drug release in HeLa cells, resulting in 88% of cell killing.	Doxorubicin	43-46	moesin	Homo sapiens	90-93	
32329202-8	2020	In vitro cytotoxicity assay indicates that DOX loaded mixture nanoparticles (ratio of PLL-MSN to PLG-MSN is 1:1) can be triggered for drug release in HeLa cells, resulting in 88% of cell killing.	Doxorubicin	43-46	moesin	Homo sapiens	101-104	
31377647-4	2019	The model drug doxorubicin (Dox) was efficiently loaded within the channels of MSN-hyd-MOP (encapsulation efficiency about 87%).	Doxorubicin	15-26	moesin	Homo sapiens	79-82	
32046364-4	2020	The optimal formulation of an MSN with polyethylene glycol (2% and 5%) and chitosan was undertaken, to produce sterically stabilized, hydrophilic MSNs, capable of efficient loading and delivery of the hydrophobic anti-neoplastic drug, doxorubicin (DOX).	Doxorubicin	235-246	moesin	Homo sapiens	30-33	
32046364-4	2020	The optimal formulation of an MSN with polyethylene glycol (2% and 5%) and chitosan was undertaken, to produce sterically stabilized, hydrophilic MSNs, capable of efficient loading and delivery of the hydrophobic anti-neoplastic drug, doxorubicin (DOX).	Doxorubicin	248-251	moesin	Homo sapiens	30-33	
32046364-7	2020	The 2% pegylated MSN formulation (PCMSN) had the highest DOX loading capacity (0.98 mgdox/mgmsn), and a sustained release profile over 72 h. Pegylated-drug nanoconjugates were effective at a concentration range between 20-50 mug/mL, inducing apoptosis in cancer cells, and affirming their potential as effective drug delivery vehicles.	Doxorubicin	57-60	moesin	Homo sapiens	17-20	
31872318-2	2019	We herein construct an efficient cell-targeting drug delivery system (Sgc8-MSN/Dox) based on aptamer-modified mesoporous silica nanoparticles that relies on the tumor-targeting ability of the aptamer Sgc8 to deliver doxorubicin (Dox) to leukemia cells in a targeted way, thereby improving therapeutic efficacy and reducing toxicity.	Doxorubicin	216-227	moesin	Homo sapiens	75-78	
31872318-2	2019	We herein construct an efficient cell-targeting drug delivery system (Sgc8-MSN/Dox) based on aptamer-modified mesoporous silica nanoparticles that relies on the tumor-targeting ability of the aptamer Sgc8 to deliver doxorubicin (Dox) to leukemia cells in a targeted way, thereby improving therapeutic efficacy and reducing toxicity.	Doxorubicin	229-232	moesin	Homo sapiens	75-78	
31872318-3	2019	In this work, Sgc8-MSN/Dox showed sustained Dox release, and they targeted and efficiently killed CCRF-CEM human acute T lymphocyte leukemia cells, suggesting potential as a cancer therapy.	Doxorubicin	23-26	moesin	Homo sapiens	19-22	
31872318-3	2019	In this work, Sgc8-MSN/Dox showed sustained Dox release, and they targeted and efficiently killed CCRF-CEM human acute T lymphocyte leukemia cells, suggesting potential as a cancer therapy.	Doxorubicin	44-47	moesin	Homo sapiens	19-22	
31377647-4	2019	The model drug doxorubicin (Dox) was efficiently loaded within the channels of MSN-hyd-MOP (encapsulation efficiency about 87%).	Doxorubicin	28-31	moesin	Homo sapiens	79-82	
31377647-5	2019	The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly.	Doxorubicin	48-51	moesin	Homo sapiens	59-62	
31377647-5	2019	The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly.	Doxorubicin	48-51	moesin	Homo sapiens	72-75	
31377647-5	2019	The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly.	Doxorubicin	84-87	moesin	Homo sapiens	59-62	
31377647-5	2019	The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly.	Doxorubicin	84-87	moesin	Homo sapiens	72-75	
31377647-5	2019	The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly.	Doxorubicin	84-87	moesin	Homo sapiens	59-62	
31377647-5	2019	The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly.	Doxorubicin	84-87	moesin	Homo sapiens	72-75	
31114189-4	2019	Then, Doxorubicin (Dox) was encapsulated into the pore of MSNs, followed by capping with tumor-targeting molecules hyaluronic acid (HA) through electrostatic interactions to form the final product consist of Dox loaded, TPP attached, HA capped mesoporous silica nanoparticles (MSN-DPH).	Doxorubicin	6-17	moesin	Homo sapiens	58-61	
31336697-6	2019	MSN@PDA loaded with doxorubicin (hydrophilic) and fingolimod (hydrophobic) was studied via a systematic in vitro approach (cellular internalization, intracellular drug distribution and cytotoxicity).	Doxorubicin	20-31	moesin	Homo sapiens	0-3	
31336697-8	2019	Drug-loaded, copolymer-coated MSN@PDA showed effective cellular uptake, intracellular release and an amplified cytotoxic effect with both doxorubicin and fingolimod.	Doxorubicin	138-149	moesin	Homo sapiens	30-33	
30959408-6	2019	Both in vitro and in vivo studies proved that LM@MSN/DOX@HA could significantly inhibit solid tumor growth under near infrared (NIR) irradiation by synergistic photothermal/chemotherapy.	Doxorubicin	53-56	moesin	Homo sapiens	49-52	
31114189-4	2019	Then, Doxorubicin (Dox) was encapsulated into the pore of MSNs, followed by capping with tumor-targeting molecules hyaluronic acid (HA) through electrostatic interactions to form the final product consist of Dox loaded, TPP attached, HA capped mesoporous silica nanoparticles (MSN-DPH).	Doxorubicin	6-9	moesin	Homo sapiens	58-61	
31114189-4	2019	Then, Doxorubicin (Dox) was encapsulated into the pore of MSNs, followed by capping with tumor-targeting molecules hyaluronic acid (HA) through electrostatic interactions to form the final product consist of Dox loaded, TPP attached, HA capped mesoporous silica nanoparticles (MSN-DPH).	Doxorubicin	19-22	moesin	Homo sapiens	58-61	
30572156-6	2019	In vivo antitumor results demonstrated that DOX/MSN@CaCO3@CM administration could remarkably suppress the tumor growth.	Doxorubicin	44-47	moesin	Homo sapiens	48-51	
30660963-2	2019	Imine bonds acted as the pH-cleavable linker between copolymer gatekeepers and MSN to promote the controlled-release performance of DOX.	Doxorubicin	132-135	moesin	Homo sapiens	79-82	
30660963-3	2019	The DOX-loaded nanoparticles (Polymer@MSN-DOX) were spherical with a diameter of approximately 150 nm.	Doxorubicin	4-7	moesin	Homo sapiens	38-41	
30660963-3	2019	The DOX-loaded nanoparticles (Polymer@MSN-DOX) were spherical with a diameter of approximately 150 nm.	Doxorubicin	42-45	moesin	Homo sapiens	38-41	
30660963-5	2019	Confocal microscopy studies and in vitro cytotoxicity results revealed that Polymer@MSN-DOX could smoothly enter HepG2 cells to release DOX and show a high cytotoxicity.	Doxorubicin	88-91	moesin	Homo sapiens	84-87	
30572156-4	2019	In vitro cell experiments demonstrated that the as-prepared nanovehicles (denoted as DOX/MSN@CaCO3@CM) could be efficiently uptaken by LNCaP-AI prostate cancer cells and even exhibited a better anti-tumor efficiency than free DOX.	Doxorubicin	226-229	moesin	Homo sapiens	89-92	
30539634-5	2019	We loaded doxorubicin (DOX) as anticancer biomolecule into the pores of MSN and capped with COP.	Doxorubicin	10-21	moesin	Homo sapiens	72-75	
30572156-5	2019	In addition, Live/Dead cell detection and apoptosis experiment demonstrated that MSN/DOX@CaCO3@CM could effectively induce apoptosis-related death in prostate cancer cells.	Doxorubicin	85-88	moesin	Homo sapiens	81-84	
30606519-5	2019	In addition, the rGO/MSN/PDA showed pH-response DOX release abilities, which means higher release of DOX in tumor cells.	Doxorubicin	48-51	moesin	Homo sapiens	21-24	
30606519-5	2019	In addition, the rGO/MSN/PDA showed pH-response DOX release abilities, which means higher release of DOX in tumor cells.	Doxorubicin	101-104	moesin	Homo sapiens	21-24	
30539634-5	2019	We loaded doxorubicin (DOX) as anticancer biomolecule into the pores of MSN and capped with COP.	Doxorubicin	23-26	moesin	Homo sapiens	72-75	
29595852-3	2018	Herein, we fabricated doxorubicin hydrochloride (DOX)- and indocyanine green (ICG)-loaded microneedle (MN) patches (PVP@DOX/MSN@ICG) using a two-step casting process.	Doxorubicin	22-47	moesin	Homo sapiens	124-127	
30102469-7	2018	Importantly, the synergistic photothermal therapy-chemotherapy of the RGD-Bi2 S3 @MSN/DOX significantly ablates the highly malignant OS.	Doxorubicin	86-89	moesin	Homo sapiens	82-85	
30102469-9	2018	Hence, the smart RGD-Bi2 S3 @MSN/DOX theranostic platform is a promising candidate for future applications in CT monitoring and synergistic treatment of malignant tumors.	Doxorubicin	33-36	moesin	Homo sapiens	29-32	
28917803-6	2018	Gate DNA were modified to the surface of the mesoporous silica (MSN) by electrostatic attraction to encapsulate DOX.	Doxorubicin	112-115	moesin	Homo sapiens	64-67	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	48-59	moesin	Homo sapiens	40-43	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	48-59	moesin	Homo sapiens	70-73	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	48-59	moesin	Homo sapiens	70-73	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	78-81	moesin	Homo sapiens	40-43	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	78-81	moesin	Homo sapiens	70-73	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	78-81	moesin	Homo sapiens	70-73	
29146540-2	2018	Due to the superior temperature-sensitive properties of ROSP, ROSP@MSN could achieve cargo loading in cold water, and subsequently close the pore by raising temperature to obtain ROSP@MSN@DOX.	Doxorubicin	188-191	moesin	Homo sapiens	62-70	
29146540-2	2018	Due to the superior temperature-sensitive properties of ROSP, ROSP@MSN could achieve cargo loading in cold water, and subsequently close the pore by raising temperature to obtain ROSP@MSN@DOX.	Doxorubicin	188-191	moesin	Homo sapiens	179-187	
29146540-3	2018	Upon the stimulus of ROS, ROSP@MSN@DOX shows good release performance at physiological conditions.	Doxorubicin	35-38	moesin	Homo sapiens	26-34	
29146540-5	2018	Furthermore, after treated with ROSP@MSN@DOX at a concentration of 100 mug/mL for 24 h, the viability of Hela cells is reduced to 40.5%; Control experiments demonstrate that, when Hela cells are pretreated with active oxygen scavenger, cell viability is about 65.3% due to the significant decrease of intracellular reactive oxygen species.	Doxorubicin	41-44	moesin	Homo sapiens	32-40	
28917803-7	2018	After the above-mentioned RCA process, its result that long DNA chain containing a base fragment complementary to gate DNA, would be hybridized to the gate DNA strand on the surface of MSN, which opened the MSN hole and released the drug DOX into cell for HeLa cell therapy.	Doxorubicin	238-241	moesin	Homo sapiens	185-188	
28917803-7	2018	After the above-mentioned RCA process, its result that long DNA chain containing a base fragment complementary to gate DNA, would be hybridized to the gate DNA strand on the surface of MSN, which opened the MSN hole and released the drug DOX into cell for HeLa cell therapy.	Doxorubicin	238-241	moesin	Homo sapiens	207-210	
28776488-1	2017	Amino-functionalized mesoporous silica nanoparticles (MSN-NH2) were synthesized by a post-grafting method and further studied as carriers for doxorubicin hydrochloride (DOX) delivery.	Doxorubicin	142-167	moesin	Homo sapiens	54-57	
28888000-5	2017	Stimulus-induced release of the DOX was studied in the different pH and GSH, which showed the embedded DOX can be controlled release from MSN channels.	Doxorubicin	32-35	moesin	Homo sapiens	138-141	
28888000-5	2017	Stimulus-induced release of the DOX was studied in the different pH and GSH, which showed the embedded DOX can be controlled release from MSN channels.	Doxorubicin	103-106	moesin	Homo sapiens	138-141	
28958879-8	2017	Of note, a transwell chamber assay demonstrated that the migration and invasion of tumour cells were markedly inhibited by ADH-1-HA-MSN/DOX.	Doxorubicin	136-139	moesin	Homo sapiens	132-135	
28958879-9	2017	Furthermore, Western blotting analysis revealed that ADH-1-HA-MSN/DOX inhibited tumour cell invasion and metastasis by down-regulating N-cadherin expression.	Doxorubicin	66-69	moesin	Homo sapiens	62-65	
28776488-1	2017	Amino-functionalized mesoporous silica nanoparticles (MSN-NH2) were synthesized by a post-grafting method and further studied as carriers for doxorubicin hydrochloride (DOX) delivery.	Doxorubicin	169-172	moesin	Homo sapiens	54-57	
28776488-2	2017	The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials.	Doxorubicin	55-58	moesin	Homo sapiens	66-69	
28776488-2	2017	The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials.	Doxorubicin	55-58	moesin	Homo sapiens	66-69	
28776488-2	2017	The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials.	Doxorubicin	75-78	moesin	Homo sapiens	66-69	
28776488-2	2017	The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials.	Doxorubicin	75-78	moesin	Homo sapiens	66-69	
28776488-4	2017	The results indicated that the loading content of DOX increased with the decrease of MSN-NH2/DOX mass ratio and/or the increase of amino density.	Doxorubicin	50-53	moesin	Homo sapiens	85-88	
28776488-5	2017	DOX@MSN-NH2 exhibited a pH-dependent drug release, drug release increased as the pH value decreased.	Doxorubicin	0-3	moesin	Homo sapiens	4-7	
28776488-6	2017	Compared with MSN-NH2, which were neglectable cytotoxicity against non-small-cell lung cancer (A549) cells, DOX@MSN-NH2 displayed remarkable cytotoxicity toward A549 cells in dose- and time-dependent manners.	Doxorubicin	108-111	moesin	Homo sapiens	112-115	
28686414-1	2017	In this paper, mesoporous silica nanoparticle (MSN) loaded with doxorubicin (DOX) and capped with tumor-homing/-penetrating peptide tLyP-1-modified tungsten disulfide quantum dots (WS2-HP) was designed and applied as a stimuli-responsive "Cluster Bomb" for high-performance tumor suppression.	Doxorubicin	64-75	moesin	Homo sapiens	47-50	
28849842-7	2017	Furthermore, photoinitiated polymerization cross-linked methacrylated hyaluronic acid (m-HA) gel was covered on the surface of DOX@MSN to improve its tumour targeting ability.	Doxorubicin	127-130	moesin	Homo sapiens	131-134	
28849842-9	2017	Importantly, subsequent US treatment could not only trigger SDT of MSN but also promote DOX release from MSN to show chemotherapeutic activity.	Doxorubicin	88-91	moesin	Homo sapiens	105-108	
28933253-10	2017	Interestingly, Moesin silencing restored the 1001 sensitivity to Doxorubicin.	Doxorubicin	65-76	moesin	Homo sapiens	15-21	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	33-44	moesin	Homo sapiens	84-87	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	33-44	moesin	Homo sapiens	193-196	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	46-49	moesin	Homo sapiens	84-87	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	46-49	moesin	Homo sapiens	193-196	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	176-179	moesin	Homo sapiens	84-87	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	176-179	moesin	Homo sapiens	193-196	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	176-179	moesin	Homo sapiens	84-87	
28363599-4	2017	Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment.	Doxorubicin	176-179	moesin	Homo sapiens	193-196	
28363599-5	2017	The results of the cell imaging and cytotoxicity studies demonstrated that the redox/enzyme dual-responsive DOX-encapsulated MSN-SS-CDHA nanoparticles can selectively deliver and control the release of DOX into tumor cells.	Doxorubicin	108-111	moesin	Homo sapiens	125-128	
28363599-5	2017	The results of the cell imaging and cytotoxicity studies demonstrated that the redox/enzyme dual-responsive DOX-encapsulated MSN-SS-CDHA nanoparticles can selectively deliver and control the release of DOX into tumor cells.	Doxorubicin	202-205	moesin	Homo sapiens	125-128	
28363599-6	2017	Ex vivo fluorescence images showed a much stronger fluorescence of MSN-SS-CDHA-DOX in the tumor site than in normal tissues, greatly facilitating the accumulation of DOX in the target tissue.	Doxorubicin	79-82	moesin	Homo sapiens	67-70	
28686414-1	2017	In this paper, mesoporous silica nanoparticle (MSN) loaded with doxorubicin (DOX) and capped with tumor-homing/-penetrating peptide tLyP-1-modified tungsten disulfide quantum dots (WS2-HP) was designed and applied as a stimuli-responsive "Cluster Bomb" for high-performance tumor suppression.	Doxorubicin	77-80	moesin	Homo sapiens	47-50	
26945977-7	2016	Additionally, HHG2C18-L became more positive at tumor intracellular pH and enhanced Coulombic repulsion with MSN-NH2, leading to increased sequential staggered release of erlotinib and DOX.	Doxorubicin	185-188	moesin	Homo sapiens	109-112	
27346782-3	2016	The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60).	Doxorubicin	15-40	moesin	Homo sapiens	219-222	
27346782-3	2016	The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60).	Doxorubicin	15-40	moesin	Homo sapiens	224-231	
27346782-3	2016	The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60).	Doxorubicin	42-45	moesin	Homo sapiens	219-222	
27346782-3	2016	The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60).	Doxorubicin	42-45	moesin	Homo sapiens	224-231	
27191965-3	2016	In this work, we developed folate (FA) receptor targeted magnetic-mesoporous silica nanoparticles for the codelivery of VEGF shRNA and doxorubicin (DOX) (denoted as M-MSN(DOX)/PEI-FA/VEGF shRNA).	Doxorubicin	135-146	moesin	Homo sapiens	167-170	
27191965-4	2016	Our data showed that M-MSN(DOX)/PEI-FA could strongly condense VEGF shRNA at weight ratios of 30:1, and possesses higher stability against DNase I digestion and sodium heparin.	Doxorubicin	27-30	moesin	Homo sapiens	23-26	
27191965-6	2016	The intracellular accumulation of DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN(DOX)/PEI-FA were more easily taken up than nontargeted M-MSN(DOX).	Doxorubicin	34-37	moesin	Homo sapiens	110-113	
27191965-6	2016	The intracellular accumulation of DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN(DOX)/PEI-FA were more easily taken up than nontargeted M-MSN(DOX).	Doxorubicin	114-117	moesin	Homo sapiens	110-113	
27191965-6	2016	The intracellular accumulation of DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN(DOX)/PEI-FA were more easily taken up than nontargeted M-MSN(DOX).	Doxorubicin	114-117	moesin	Homo sapiens	110-113	
27016140-4	2016	The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers.	Doxorubicin	17-28	moesin	Homo sapiens	118-128	
27016140-4	2016	The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers.	Doxorubicin	17-28	moesin	Homo sapiens	118-121	
27016140-4	2016	The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers.	Doxorubicin	30-33	moesin	Homo sapiens	118-128	
27016140-4	2016	The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers.	Doxorubicin	30-33	moesin	Homo sapiens	118-121	
28407530-7	2017	Apoptosis analysis confirmed that DOX and p53 could be co-delivered to the Hela cells by MSN-SS-CP nanocarriers and induced significant cell apoptosis.	Doxorubicin	34-37	moesin	Homo sapiens	89-92	
28174081-6	2017	And from which DOX@MSN-NH-N=C-PAD10 is chosen as the most satisfactory one for the further in vitro cytotoxicity studies and cellular uptake studies.	Doxorubicin	15-18	moesin	Homo sapiens	19-22	
28174081-7	2017	The results demonstrate that DOX@MSN-NH-N=C-PAD10 with an excellent pH-sensitivity can enter HeLa cells to release DOX intracellular due to the weakly acidic pH intracellular and kill the cells.	Doxorubicin	29-32	moesin	Homo sapiens	33-36	
28174081-7	2017	The results demonstrate that DOX@MSN-NH-N=C-PAD10 with an excellent pH-sensitivity can enter HeLa cells to release DOX intracellular due to the weakly acidic pH intracellular and kill the cells.	Doxorubicin	115-118	moesin	Homo sapiens	33-36	
25985912-7	2015	The DOX-loaded MSN-SS-HA was more cytotoxic against HCT-116 cells than NIH-3T3 (CD44 receptor-negative) cells due to the enhanced cellular uptake of MSN-SS-HA.	Doxorubicin	4-7	moesin	Homo sapiens	15-18	
26878288-1	2016	In this study, dual functionalized mesoporous silica nanoparticle (Dual-MSN) with functions of carboxyl modification and chirality was successfully developed and its special contribution in delivering doxorubicin hydrochloride (DOX) in vitro was mainly studied.	Doxorubicin	201-226	moesin	Homo sapiens	72-75	
26878288-1	2016	In this study, dual functionalized mesoporous silica nanoparticle (Dual-MSN) with functions of carboxyl modification and chirality was successfully developed and its special contribution in delivering doxorubicin hydrochloride (DOX) in vitro was mainly studied.	Doxorubicin	228-231	moesin	Homo sapiens	72-75	
26878288-2	2016	Characteristics of Dual-MSN and its application as DOX carrier were intensively explored by comparing with naked non-functionalized MSN (Naked MSN).	Doxorubicin	51-54	moesin	Homo sapiens	24-27	
26878288-3	2016	The results indicated that both Naked MSN and Dual-MSN significantly controlled DOX release due to the release hindrance caused by mesopores.	Doxorubicin	80-83	moesin	Homo sapiens	38-41	
26878288-3	2016	The results indicated that both Naked MSN and Dual-MSN significantly controlled DOX release due to the release hindrance caused by mesopores.	Doxorubicin	80-83	moesin	Homo sapiens	51-54	
26878288-5	2016	DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei.	Doxorubicin	0-3	moesin	Homo sapiens	17-20	
26878288-5	2016	DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei.	Doxorubicin	0-3	moesin	Homo sapiens	41-44	
26878288-5	2016	DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei.	Doxorubicin	25-28	moesin	Homo sapiens	41-44	
26878288-5	2016	DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei.	Doxorubicin	25-28	moesin	Homo sapiens	41-44	
26878288-5	2016	DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei.	Doxorubicin	25-28	moesin	Homo sapiens	41-44	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	20-23	moesin	Homo sapiens	36-39	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	36-39	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	36-39	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	36-39	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
26878288-6	2016	The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery.	Doxorubicin	56-59	moesin	Homo sapiens	73-76	
32263193-7	2016	The application potential of the PDA-MSN hybrid nanocarriers is demonstrated by an unprecedentedly high drug (DOX) loading capacity of 1000 mg g-1, a sustained drug release, as well as enhanced killing efficiency of cancer cells at low dosage.	Doxorubicin	110-113	moesin	Homo sapiens	37-40	
26690044-5	2016	Results demonstrated that EpCAM conjugation increased binding of Ap-MSN-DOX to EpCAM over-expressing SW620 colon cancer cells but not EpCAM-negative Ramos cells, resulting in enhanced cellular uptake and increased cytotoxicity of the DOX in SW620 cells when compared to non-Ap-modified nanoparticles (MSN-DOX).	Doxorubicin	72-75	moesin	Homo sapiens	68-71	
26690044-5	2016	Results demonstrated that EpCAM conjugation increased binding of Ap-MSN-DOX to EpCAM over-expressing SW620 colon cancer cells but not EpCAM-negative Ramos cells, resulting in enhanced cellular uptake and increased cytotoxicity of the DOX in SW620 cells when compared to non-Ap-modified nanoparticles (MSN-DOX).	Doxorubicin	72-75	moesin	Homo sapiens	301-304	
26690044-5	2016	Results demonstrated that EpCAM conjugation increased binding of Ap-MSN-DOX to EpCAM over-expressing SW620 colon cancer cells but not EpCAM-negative Ramos cells, resulting in enhanced cellular uptake and increased cytotoxicity of the DOX in SW620 cells when compared to non-Ap-modified nanoparticles (MSN-DOX).	Doxorubicin	234-237	moesin	Homo sapiens	68-71	
26690044-6	2016	Additionally, Ap-MSN-DOX exhibited significant inhibition effects on the expression of EpCAM on SW620 cells.	Doxorubicin	21-24	moesin	Homo sapiens	17-20	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	0-11	moesin	Homo sapiens	64-67	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	0-11	moesin	Homo sapiens	79-82	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	13-16	moesin	Homo sapiens	64-67	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	13-16	moesin	Homo sapiens	79-82	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	53-56	moesin	Homo sapiens	64-67	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	53-56	moesin	Homo sapiens	79-82	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	53-56	moesin	Homo sapiens	64-67	
32262716-6	2015	Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system.	Doxorubicin	53-56	moesin	Homo sapiens	79-82	
32261575-3	2014	The results show that the CytC capped nanocarriers have excellent doxorubicin (DOX) loading efficiency (414 mug mg-1 MSN) and the leakage of the drug is only 16% at pH 7.4 phosphate-buffered saline for 72 h. Simultaneously, the DOX release percentage can reach 54% by decreasing the pH to 5.5.	Doxorubicin	79-82	moesin	Homo sapiens	117-120	
25620848-10	2014	In vivo tumor-growth inhibition experiments with BALB/c nude mice demonstrated a highly efficient tumor-growth inhibition rate of DOX-loaded LbL-MSNs, suggesting that the novel type of LbL-MSN materials hold great potentials in anticancer drug delivery.	Doxorubicin	130-133	moesin	Homo sapiens	145-148	
26505004-3	2015	The as-synthesized HMSN-PEG nanoparticles exhibited higher loading capacity of anticancer drug (Doxorubicin) and better sustained release property than MSN and MSN-PEG particles.	Doxorubicin	96-107	moesin	Homo sapiens	20-23	
26505004-6	2015	Furthermore, the DOX-loaded HMSN-PEG nanoparticles exhibited higher cytotoxicity than the DOX-loaded MSN and MSN-PEG nanoparticles against Hep-G2 cells.	Doxorubicin	17-20	moesin	Homo sapiens	29-32	
26505004-6	2015	Furthermore, the DOX-loaded HMSN-PEG nanoparticles exhibited higher cytotoxicity than the DOX-loaded MSN and MSN-PEG nanoparticles against Hep-G2 cells.	Doxorubicin	90-93	moesin	Homo sapiens	101-104	
24980623-7	2014	The M-MSN were loaded with anticancer drug Doxorubicin and the efficacy of the DOX loaded M-MSN was evaluated through in vitro cytotoxicity, fluorescence microscopy, and apoptosis studies.	Doxorubicin	79-82	moesin	Homo sapiens	6-9	
24980623-7	2014	The M-MSN were loaded with anticancer drug Doxorubicin and the efficacy of the DOX loaded M-MSN was evaluated through in vitro cytotoxicity, fluorescence microscopy, and apoptosis studies.	Doxorubicin	79-82	moesin	Homo sapiens	92-95	
23997043-5	2014	To achieve targeting therapy, an anticancer drug, doxorubicin (Dox), was loaded into MSN@Alg, and a arginine, glycine, and aspartic acid (RGD)-based peptide was functionalized onto the surface of MSN@Alg for the purpose of specific targeting.	Doxorubicin	63-66	moesin	Homo sapiens	85-88	
24940057-4	2014	For targeting therapy, the anticancer drug doxorubicin was loaded into MSN@Alg microspheres, and the (lysine)4-tyrosine-arginine-glycine-aspartic acid (K4YRGD) peptide was functionalized onto the surface of MSN@Alg for targeting liver cancer cells, hepatocellular carcinoma (HepG2).	Doxorubicin	43-54	moesin	Homo sapiens	71-74	
24940057-4	2014	For targeting therapy, the anticancer drug doxorubicin was loaded into MSN@Alg microspheres, and the (lysine)4-tyrosine-arginine-glycine-aspartic acid (K4YRGD) peptide was functionalized onto the surface of MSN@Alg for targeting liver cancer cells, hepatocellular carcinoma (HepG2).	Doxorubicin	43-54	moesin	Homo sapiens	207-210	
24940057-6	2014	In addition, the intracellular drug delivery efficiency was greatly enhanced (ie, 3.5-fold) for the arginine-glycine-aspartic acid (RGD)-labeled, doxorubicin-loaded MSN@Alg drug delivery system compared with the non-RGD case.	Doxorubicin	146-157	moesin	Homo sapiens	165-168	
24392791-5	2014	Unique changes in gene expressions and gene ontology terms, which were caused only by the MSN-based DDS (DOX-loaded MSNs, DOX@MSNs) but not by free drug doxorubicin (DOX) and/or the carrier MSNs, were discovered and proposed to be responsible for the varied cell death mechanisms, including the greatly enhanced necrosis due to amplified oxidative stress and the apoptosis related with DNA/RNA synthesis and cell cycle inhibitions.	Doxorubicin	105-108	moesin	Homo sapiens	90-93	
24392791-5	2014	Unique changes in gene expressions and gene ontology terms, which were caused only by the MSN-based DDS (DOX-loaded MSNs, DOX@MSNs) but not by free drug doxorubicin (DOX) and/or the carrier MSNs, were discovered and proposed to be responsible for the varied cell death mechanisms, including the greatly enhanced necrosis due to amplified oxidative stress and the apoptosis related with DNA/RNA synthesis and cell cycle inhibitions.	Doxorubicin	122-125	moesin	Homo sapiens	90-93	
24392791-5	2014	Unique changes in gene expressions and gene ontology terms, which were caused only by the MSN-based DDS (DOX-loaded MSNs, DOX@MSNs) but not by free drug doxorubicin (DOX) and/or the carrier MSNs, were discovered and proposed to be responsible for the varied cell death mechanisms, including the greatly enhanced necrosis due to amplified oxidative stress and the apoptosis related with DNA/RNA synthesis and cell cycle inhibitions.	Doxorubicin	122-125	moesin	Homo sapiens	90-93	
23997043-5	2014	To achieve targeting therapy, an anticancer drug, doxorubicin (Dox), was loaded into MSN@Alg, and a arginine, glycine, and aspartic acid (RGD)-based peptide was functionalized onto the surface of MSN@Alg for the purpose of specific targeting.	Doxorubicin	50-61	moesin	Homo sapiens	85-88	
23997043-6	2014	The results showed that the intracellular drug delivery efficiency was greatly enhanced (i.e., 3.5-folds) for the Dox/MSN@Alg-RGD drug delivery system.	Doxorubicin	114-117	moesin	Homo sapiens	118-121	
32261387-6	2014	In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity.	Doxorubicin	79-82	moesin	Homo sapiens	98-101	
32261387-6	2014	In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity.	Doxorubicin	79-82	moesin	Homo sapiens	115-118	
32261387-6	2014	In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity.	Doxorubicin	103-106	moesin	Homo sapiens	98-101	
32261387-6	2014	In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity.	Doxorubicin	103-106	moesin	Homo sapiens	115-118	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	26-51	moesin	Homo sapiens	74-77	
32263329-3	2013	Here, we report hybrid mesoporous nanoparticles of PEGylated silica-poly[2-(dimethylamino)ethyl acrylate] (PEGylated MSN-g-PDMAEA) that can deliver and release the anti-cancer drug doxorubicin (DOX) to tumor cells in a pH dependent switch on/off status.	Doxorubicin	181-192	moesin	Homo sapiens	117-120	
32263329-3	2013	Here, we report hybrid mesoporous nanoparticles of PEGylated silica-poly[2-(dimethylamino)ethyl acrylate] (PEGylated MSN-g-PDMAEA) that can deliver and release the anti-cancer drug doxorubicin (DOX) to tumor cells in a pH dependent switch on/off status.	Doxorubicin	194-197	moesin	Homo sapiens	117-120	
24073830-7	2013	After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately.	Doxorubicin	50-53	moesin	Homo sapiens	82-85	
24073830-7	2013	After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately.	Doxorubicin	50-53	moesin	Homo sapiens	99-102	
24073830-7	2013	After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately.	Doxorubicin	71-74	moesin	Homo sapiens	82-85	
24073830-7	2013	After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately.	Doxorubicin	71-74	moesin	Homo sapiens	99-102	
23711784-4	2013	The functionalization with carboxyl caused the pore surface of the nanocarrier more negative than native MSN, which could provide attractive forces between the nanoparticles and positively charged doxorubicin hydrochloride (DOX).	Doxorubicin	197-222	moesin	Homo sapiens	105-108	
23711784-4	2013	The functionalization with carboxyl caused the pore surface of the nanocarrier more negative than native MSN, which could provide attractive forces between the nanoparticles and positively charged doxorubicin hydrochloride (DOX).	Doxorubicin	224-227	moesin	Homo sapiens	105-108	
32261203-5	2013	The results showed that DOX-loaded MSNs were successfully incorporated into composite nanofibers with different MSN (or DOX) contents.	Doxorubicin	24-27	moesin	Homo sapiens	35-38	
32261203-5	2013	The results showed that DOX-loaded MSNs were successfully incorporated into composite nanofibers with different MSN (or DOX) contents.	Doxorubicin	120-123	moesin	Homo sapiens	35-38	
32261203-6	2013	Among them, the PLLA/1.0% DOX@10% MSN nanofibers exhibited good particle distribution and improved thermal stability.	Doxorubicin	26-29	moesin	Homo sapiens	34-37	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	26-51	moesin	Homo sapiens	88-91	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	53-56	moesin	Homo sapiens	74-77	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	53-56	moesin	Homo sapiens	88-91	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	63-66	moesin	Homo sapiens	74-77	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	63-66	moesin	Homo sapiens	88-91	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	63-66	moesin	Homo sapiens	74-77	
23598077-3	2013	The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4.	Doxorubicin	63-66	moesin	Homo sapiens	88-91	
23598077-4	2013	The cytotoxicity results indicated that the blank MSN-PLGA was biocompatible and the DOX@MSN-PLGA had potent in vitro cytotoxicity effect similar to free DOX.	Doxorubicin	85-88	moesin	Homo sapiens	50-53	
23598077-4	2013	The cytotoxicity results indicated that the blank MSN-PLGA was biocompatible and the DOX@MSN-PLGA had potent in vitro cytotoxicity effect similar to free DOX.	Doxorubicin	85-88	moesin	Homo sapiens	89-92	
22019849-4	2011	The in vitro release profiles of DOX from the MSN-based prodrug systems showed a strong dependence on the environmental pH values.	Doxorubicin	33-36	moesin	Homo sapiens	46-49	
23543911-6	2013	The in vitro cell culture experiments showed that not only PNiPAM/AA@SiO2 particles were more biocompatible and lower cytotoxic than MSN, but also DOX@PNiPAM/AA@SiO2 had higher drug releasing efficiency in the lysosomes and stronger inhibitory effect on tumor cell growth than DOX@MSN.	Doxorubicin	147-150	moesin	Homo sapiens	281-284